MarginsXMarginsX
Home › Markets › Health Care › OCS

Oculis Holding AG (OCS)

OCS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.63
-0.13% on the day
Market cap
$469.9M
Small cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerOCS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountrySwitzerland
IPO yearNot reported by the screener
SEC CIK0001953530
SEC industry codePharmaceutical Preparations
Incorporated inSwitzerland

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
14.7 months
81.3M CHF cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed March 4, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-04
Cash and burn81.3M CHF cash; operating cash flow -16.6M CHF a quarter.Report 2025-12-31
Shares outstanding57,984,438 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-11-03
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers AG, Lausanne, SwitzerlandPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-99.0M CHF-66.3M CHF81.3M CHFNo debt tagsNeeds four quarters20-F 2026-03-04
FY 2024
2024-12-31
Not filed-85.8M CHF-48.9M CHF27.7M CHFNo debt tagsNeeds four quarters20-F 2026-03-04
FY 2023
2023-12-31
Not filed-88.8M CHF-55.0M CHF38.3M CHFNo debt tagsNeeds four quarters20-F 2026-03-04
FY 2022
2022-12-31
Not filed-38.7M CHF-25.1M CHF19.8M CHFNo debt tagsNeeds four quarters20-F 2025-03-11
FY 2021
2021-12-31
Not filed-18.6M CHF-13.8M CHF46.3M CHFNo debt tagsNeeds four quarters20-F 2024-03-19
FY 2020
2020-12-31
Not filed-14.9M CHF-12.0M CHF5.0M CHFNo debt tagsNeeds four quarters20-F 2023-03-28

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CHF.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-03
Latest annual report20-F2026-03-04
Latest quarterly / interim6-K2026-11-03

Source: SEC EDGAR submissions feed, 138 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.0%
1 month+0.3%
3 months-40.4%
Year to date-61.7%
1 year-60.4%
From 52-week high-76.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
OCSAWOculis Holding AG Warrants$1.90

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LYELLyell Immunopharma Inc.$14.65+2.45%$469.0M
KMDAKamada Ltd.$8.11+0.25%$468.0M
AQSTAquestive Therapeutics Inc.$3.76-3.84%$472.6M
STTKShattuck Labs Inc.$4.66+0.21%$474.6M
PHATPhathom Pharmaceuticals Inc.$5.88-2.97%$478.0M
NGNENeurogene Inc. Common Stock$23.30-2.63%$482.3M
CAPRCapricor Therapeutics Inc.$8.30-12.91%$482.6M
OVIDOvid Therapeutics Inc.$2.40-5.51%$453.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier